PUBLIC COMPANY
save$CNTXContext Therapeutics Inc.
$CNTXPhiladelphia, PA, USupdated 21d ago
community read0 votes
pipeline
2
marketed
0
phase 3
0
catalysts ytd
0
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- phase1CT-95 in Advanced Cancers Associated With Mesothelin Expression
- phase1A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers
- phase1A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
- phase2Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer
- phase2A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer
🐶 Hiring Signal
News
- Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027Context Therapeutics has stopped development of the bispecific T-cell engager CT-95, freeing up cash to extend its runway beyond readouts on its two priority clinical programs.fiercebiotech · 15d ago
- Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trialA phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on…fiercebiotech · 1mo ago
Data sources
last refreshed 39m ago
Found something off?
comments(0)
5-min edit window · permanent after that